Market Scale and Forecast Trajectory
The global automated ambulatory blood pressure monitoring market is projected to reach USD 0.41 billion by 2030, expanding at a compound annual growth rate of 8.7% over the forecast period. This growth rate positions the category as a steady-expansion medical device segment rather than a high-growth emerging technology—a characterization consistent with the market’s structural characteristics: established clinical guidelines, reimbursement pathways in developed markets, and a concentrated supplier base with long qualification cycles.

Independent estimates present a range of perspectives that contextualize the market’s trajectory. QYResearch’s December 2025 analysis of the automatic ABPM market places the 2032 forecast at USD 477 million with an 8.6% CAGR . A more recent January 2026 estimate positions the 2025 global market at USD 323 million, projecting USD 582 million by 2032 at an 8.9% CAGR, with 2025 production volume of 424,000 units at an average price of USD 634 per unit and gross margins around 30% . These figures bracket the original QYResearch projection and confirm the directional signal: high-single-digit growth, driven by hypertension prevalence and clinical guideline adoption rather than by a single disruptive demand driver.

The application profile reinforces where the market’s volume resides. Hospital applications account for 60.40% of demand, reflecting the concentration of ABPM initiation in clinical settings where physicians order the test, fit the device, and interpret the results. Ordinary ABPM devices hold 92.64% of the product segment, confirming that the market remains overwhelmingly cuff-based, recorder-and-cuff architectures rather than wearable or cuffless alternatives. The emerging mobile-based ABPM segment, while small in absolute terms, represents the fastest-growing product category as smartphone connectivity and app-based reporting become standard expectations .

Competitive Landscape: Concentration and the Clinical Validation Moat
The automated ABPM market exhibits moderate concentration consistent with its clinical validation requirements and limited supplier base. In 2023, the global top three players—A&D, Hill-Rom, and Halma (including SunTech Medical)—collectively accounted for approximately 42.22% of market revenue. This concentration reflects the specialized expertise required to achieve and maintain clinical validation against ISO 81060-2 standards, which is a prerequisite for regulatory clearance and clinical acceptance.

A&D’s position illustrates the incumbent archetype. The TM-2441 ABPM features an all-in-one design with 24-hour monitoring, self-measurement modes for office, home, and nighttime readings, USB and Bluetooth Low Energy connectivity, and ISO 81060-2:2013 compliance . The device’s pulse correction algorithm and multi-sensor capability—recording activity, temperature, and atmospheric pressure alongside blood pressure—represent incremental differentiation that addresses the clinical need for contextual data during monitoring. The included ABPM Data Manager software enables waveform review for each measurement, allowing clinicians to verify measurement accuracy rather than accepting automated readings at face value .

The competitive frontier is being reshaped by two parallel developments that threaten the traditional ABPM value proposition. First, the 2025 AHA/ACC guideline’s elevation of HBPM over ABPM for longitudinal management represents a significant shift in clinical practice recommendations. The guideline recommends either ABPM or HBPM for initial hypertension diagnosis, but explicitly prefers HBPM over ABPM for ongoing monitoring and medication titration in treated patients . The rationale is pragmatic: HBPM is more reproducible, more accessible, and better supported by randomized controlled trial evidence for treatment adjustment when combined with patient education and telehealth counseling. ABPM’s evidence advantage—its stronger association with cardiovascular events—is acknowledged but does not translate into application priority for longitudinal care .

Second, wearable blood pressure technologies are beginning to offer ABPM functionality in form factors that eliminate the bulky recorder and inconvenient cuff inflation cycles that drive patient non-compliance. Huawei’s Watch D3, launched in Europe and the UK in October 2026 at £399.99, incorporates a micro-pump and 25.5 mm inflatable airbag cuff within the watch band, measuring blood pressure oscillometrically—the same principle as traditional cuff devices—and supporting 24-hour ambulatory monitoring with automatic nighttime measurements and quieter cuff inflation . Critically, the blood pressure and ABPM functions carry CE medical device certification in Europe . Hilo Core, launched in the US in July 2026, takes a different approach: cuffless optical monitoring calibrated by periodic cuff readings, capturing 30–35 readings per day including overnight insights, with FDA-cleared connected cuff for validation . These wearables do not yet match the clinical validation depth of dedicated ABPM devices, but they are closing the usability gap that has historically limited ABPM adoption.

Technical Drivers: From 24-Hour Recording to Patient-Centered Data Capture
The functional case for ABPM rests on a clinical imperative that office blood pressure measurement cannot satisfy: the identification of white-coat hypertension, masked hypertension, and nocturnal hypertension, all of which require out-of-office measurement to diagnose accurately. The 24-hour recording captures blood pressure during routine activities and sleep, providing a profile that correlates more strongly with cardiovascular risk than isolated office readings.

The technical differentiation among leading ABPM devices lies not in the measurement principle—oscillometry is universal—but in the fidelity of data capture and the burden imposed on the patient. A&D’s TM-2441 addresses data fidelity through waveform recording: the device stores the oscillometric waveform for each measurement, and the software allows clinicians to review the waveform and confirm that the automated reading was derived from a valid measurement rather than an artifact . This capability is clinically meaningful: false readings from movement artifact or cuff displacement during sleep can lead to misdiagnosis, and waveform review provides a quality check that automated numeric output alone cannot.

The patient burden dimension is where wearables are mounting their challenge. Traditional ABPM requires wearing a recorder on a belt or shoulder strap, with a cuff on the upper arm connected by a tube. Nighttime measurements involve cuff inflation to pressures that frequently disrupt sleep, and the bulk of the equipment limits mobility and clothing choices. Huawei’s Watch D3 addresses this by integrating the cuff into the watch band and using a quieter inflation mechanism for nighttime readings . Hilo Core eliminates cuff inflation entirely for routine readings, using optical signals calibrated by periodic cuff measurements . Neither device has yet been validated for the full range of clinical indications that dedicated ABPM serves, but the trajectory is clear: the usability barrier that has limited ABPM compliance is being systematically eroded.

Restraints: Guideline Positioning and the Cost-Compliance Trade-off
The principal restraint on ABPM market expansion is not technical but clinical: the 2025 guideline’s positioning of ABPM as primarily a diagnostic tool rather than a management tool narrows the addressable use case. If ABPM is ordered once for diagnosis and HBPM is used thereafter for titration, the per-patient ABPM utilization rate declines. The guideline authors acknowledge that ABPM is more frequently used in treated patients in practice, contrary to the recommendation, and suggest that ABPM remains appropriate for treated patients who are unable or unwilling to perform standardized HBPM, or in cases of office-home BP disagreement and suspected nocturnal hypertension . But the recommendation signals a shift in clinical enthusiasm that device manufacturers must navigate.

The second restraint is cost, particularly in markets without comprehensive reimbursement. At an average price of USD 634 per unit, ABPM devices represent a capital and consumable cost that limits adoption in resource-constrained settings . The device itself is reusable, but the cuff and tubing are subject to wear and infection control requirements that generate recurring costs. In markets where HBPM devices costing tens of dollars are available and guideline-endorsed, the economic case for ABPM is harder to make except in diagnostic centers and specialized hypertension clinics.

A third restraint is the data interpretation burden. ABPM generates a large volume of readings—typically 40–60 measurements over 24 hours—and accurate interpretation requires expertise in identifying artifact, recognizing nocturnal patterns, and correlating readings with activity and sleep logs. The original QYResearch analysis correctly identifies this as a restraint: healthcare professionals may need additional training, and the time required for interpretation limits the number of studies a clinic can process. Automated analysis software reduces but does not eliminate this burden, and the increasing volume of data from wearable-adjacent devices may exacerbate rather than alleviate it.

Strategic Outlook
Three observations merit consideration for stakeholders positioning against the 2030 horizon.

First, the ABPM market’s 8.7% CAGR is real but vulnerable to guideline positioning. The growth is driven by hypertension prevalence—the WHO estimates over 1.4 billion people affected globally, with approximately 10 million deaths annually attributed to elevated blood pressure —and by the clinical necessity of out-of-office measurement for accurate diagnosis. But the 2025 guideline’s preference for HBPM in longitudinal management means that ABPM’s addressable market is increasingly concentrated in the diagnostic encounter rather than the chronic management pathway. Vendors should anticipate that unit growth will be driven by diagnostic volume and by emerging markets where ABPM infrastructure is being established, rather than by expansion of monitoring frequency per patient.

Second, the wearable threat is real but not yet decisive. Huawei’s Watch D3 and Hilo Core demonstrate that ABPM functionality can be delivered in form factors that patients will actually wear, and the CE certification of Watch D3’s ABPM function establishes a regulatory pathway that other wearables will follow . However, these devices have not been validated for the full range of clinical indications—particularly nocturnal hypertension and resistant hypertension—where dedicated ABPM remains the reference standard. The strategic question for traditional ABPM vendors is whether to compete on clinical validation depth or to adapt their form factors toward wearability. The former is defensible but limits the market to clinical specialties; the latter requires competing with consumer electronics companies on usability and price, a contest that medical device incumbents are not well-positioned to win.

Third, the mobile-based ABPM segment represents the most viable growth pathway for traditional vendors. The integration of smartphone connectivity, app-based reporting, and cloud data sharing addresses the interpretation burden and enables remote review by hypertension specialists. A&D’s Bluetooth connectivity and data manager software are steps in this direction , but the market is moving toward platforms that integrate ABPM data with electronic health records, home BP readings, and medication adherence data. Vendors that position ABPM as a data source within a broader hypertension management platform, rather than as a standalone diagnostic device, will be better positioned to capture value as the clinical workflow evolves.

The automated ABPM market through 2030 will not be transformed by a single technology disruption. It will be shaped by the industry’s ability to reconcile the clinical necessity of out-of-office measurement with the guideline-driven preference for home monitoring and the patient-driven demand for wearable form factors—a reconciliation in which the device that captures validated data with minimal burden, not the device that measures most precisely, captures the strategic premium.

Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp